Le Lézard
Classified in: Health, Science and technology, Business
Subject: AWD

MIRUS BIO NAMED A TOP WORKPLACE BY THE WISCONSIN STATE JOURNAL


MADISON, Wis., March 26, 2024 /PRNewswire/ -- Mirus Bio, a life sciences company developing innovative solutions for nucleic acid delivery to support cell and gene therapy production, biopharmaceutical manufacturing, and discovery applications, has been named a Top Workplace 2024 by Wisconsin State Journal Top Workplaces. This award is based solely on employee feedback collected from a survey administered by an external organization. The confidential survey measures the employee experience and perceptions related to a number of topics including whether they feel respected, supported and empowered, and have opportunities to grow.

"We are extremely proud to be recognized as a great place to work," said Dale Gordon, CEO of Mirus Bio. "Delivering excellence for our customers begins with an exceptional team and a company culture that inspires and recognizes innovation, teamwork, and dedication to our mission. We've always known that Mirus Bio is an outstanding organization with people who genuinely care for each other. It is especially gratifying to receive this award which is based on direct feedback from our amazing team."

"Earning a Top Workplaces award is a badge of honor for companies, especially because it comes authentically from their employees," said Eric Rubino, CEO of Energage, the company that administered the survey. "That's something to be proud of. In today's market, leaders must ensure they're allowing employees to have a voice and be heard. That's paramount. Top Workplaces do this, and it pays dividends."

ABOUT MIRUS BIO

Mirus Bio is a leading provider of transfection products for the biopharmaceutical and research industries, offering best-in-class reagents for gene therapy, recombinant protein, and stem cell applications. A pioneer in nucleic acid delivery, the company has been enabling scientific research and innovation for more than two decades. In 2021, Mirus introduced VirusGEN® GMP Transfection Reagent and Enhancers to address the commercial biopharmaceutical and cell and gene therapy markets with support for virus manufacturing, gene editing, and biotherapeutic protein production. For more information, visit www.mirusbio.com or follow us on LinkedIn.

COMPANY CONTACT
Mirus Bio
[email protected], 608-441-2852
https://www.mirusbio.com

ABOUT ENERGAGE
Making the world a better place to work?together.tm
Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces.?Built on 18 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, ?Energage delivers the most accurate competitive benchmark available.?With access to a unique combination of?patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture.?For more information or to nominate your organization,?visit energage.com or topworkplaces.com.

SOURCE Mirus Bio LLC


These press releases may also interest you

at 09:40
The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering. The global RNAi therapeutics...

at 09:31
RSi, a privately held revenue cycle management service provider that exclusively services hospitals and healthcare systems, has been awarded five 2024 Top Workplace honors. The awards were recently announced by the HR employee engagement technology...

at 09:30
Michael Karlfeldt, ND, PhD, Nasha Winters, ND, FABNO, LAc, DiplOM, and 40+ Experts Gather to Share the Latest Breakthroughs in Cancer Treatment Key Takeaways: The Cancer Breakthroughs Summit 2.0 aims to transform fear into confidence by providing...

at 09:26
Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today presented final data from a diabetic foot ulcer (DFU) clinical trial showing that Omeza® OCMtm plus offloading of weight on the...

at 09:25
The "China Biological Reagents Market (Molecular Biology Reagents, Proteins and Cell Reagents): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering. The China biological...

at 09:25
Illumina, Inc. today announced that its executives will be speaking at the following investor conference: RBC 2024 Global Healthcare Conference on May 14, 2024Fireside chat at 5:30am Pacific Time (8:30am Eastern Time)The webcast can be accessed...



News published on and distributed by: